KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $44.4 million.

  • Aurinia Pharmaceuticals' Cash from Operations rose 16101.94% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year increase of 32014.97%. This contributed to the annual value of $44.4 million for FY2024, which is 23265.59% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Cash from Operations of $44.4 million as of Q3 2025, which was up 16101.94% from $44.2 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Cash from Operations' 5-year high stood at $44.4 million during Q3 2025, with a 5-year trough of -$53.5 million in Q1 2021.
  • Moreover, its 5-year median value for Cash from Operations was -$13.3 million (2023), whereas its average is -$7.2 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Cash from Operations surged by 1269.12% in 2022 and then surged by 66061.57% in 2024.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Cash from Operations stood at -$25.9 million in 2021, then surged by 140.31% to $10.4 million in 2022, then surged by 36.96% to $14.3 million in 2023, then surged by 110.41% to $30.1 million in 2024, then soared by 47.6% to $44.4 million in 2025.
  • Its Cash from Operations was $44.4 million in Q3 2025, compared to $44.2 million in Q2 2025 and $1.3 million in Q1 2025.